Rezdiffra
What Rezdiffra is used for
Rezdiffra is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (fibrosis stages F2 to F3).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Rezdiffra
- Active substance
- resmetirom
- Disease area
- Non-alcoholic Fatty Liver Disease; Liver Cirrhosis
- Medicine group
- Bile and liver therapy
- ATC code
- A05
- Marketing authorisation holder
- Madrigal Pharmaceuticals EU Limited
- Authorised in the EU since
- 2025
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rezdiffra used for?
Rezdiffra is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (fibrosis stages F2 to F3).
What is the active substance in Rezdiffra?
Rezdiffra contains resmetirom.
Who makes Rezdiffra?
The EU marketing authorisation holder is Madrigal Pharmaceuticals EU Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU